



3 April 2023

ASX Announcement Release of Securities from Escrow

MELBOURNE Australia, 3 April 2023: Australian mid-clinical stage antiviral drug development company, Island Pharmaceuticals Ltd (ASX: ILA) advises, in accordance with ASX Listing Rule 3.10A, that the following securities will be released from escrow on 13 April 2023:

Security	Number
Ordinary Securities	38,022,140
Options Expiring 30 April 2024	177,778
Options Expiring 30 April 2024	177,778
Options Expiring 30 April 2024	177,777
Options Expiring 30 April 2024	3,925,000
Options Expiring 13 April 2024	3,669,744

Approved for release to the ASX by:

Dr Paul MacLeman
Executive Chairman
Island Pharmaceuticals Ltd
info@islandpharmaceuticals.com

Investors and media, for further information, please contact:

Jane Lowe
IR Department
Mobile: +61 411 117 774
jane.lowe@irdepartment.com.au

About Island Pharmaceuticals

Island (ASX: ILA) is a clinical-stage drug repurposing company, developing antiviral therapeutics to address infectious diseases. Our lead asset is ISLA-101, a drug with a well-established safety profile, being repurposed for the prevention and treatment of dengue fever and other mosquito (or vector) borne diseases. The Company is moving rapidly into clinical trials for dengue-infected subjects.

If ISLA-101 achieves FDA approval, and certain other criteria are met, Island may be eligible to obtain a "Priority Review Voucher" at the time of FDA approval. This means that as well as getting approval to manufacture and sell ISLA-101, the Priority Review Voucher (PRV) could permit Island to expedite the FDA approval process for a new drug or sell the PRV in a secondary market.

Island encourages all current investors to go paperless by registering their details with the Company's share registry, Automic Registry Services, whose contact info is housed on the Shareholder Services page of the Company's website. Visit www.islandpharmaceuticals.com for more on Island.